Antibody Technologies market research reports by DelveInsight

• Anti-CD152 Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti-CD152 Antibody - Pipeline Insight, 2024 “Anti-CD152 Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD152 Antibody development. The report provides detailed coverag ... Read More

• Myasthenia Gravis - Market Insight, Epidemiology And Market Forecast - 2034

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 7,950

  Myasthenia Gravis - Market Insight, Epidemiology And Market Forecast - 2034 Key Highlights The main treatment options for ALL include chemotherapy, targeted therapy, immunotherapy, surgery, radiation therapy, and stem cell transplant. In the last few years, immunotherapy has undergone a new phase of ... Read More

• Anti GM-CSF Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti GM-CSF Antibody - Pipeline Insight, 2024 “Anti GM-CSF Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti GM-CSF Antibody development. The report provides detailed cove ... Read More

• Anti-Mucin 1 (MUC1) Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti-Mucin 1 (MUC1) Antibody - Pipeline Insight, 2024 “Anti-Mucin 1 (MUC1) Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-Mucin 1 (MUC1) Antibody development. The repor ... Read More

• Anti-CD19 Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti-CD19 Antibody - Pipeline Insight, 2024 “Anti-CD19 Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD19 Antibody development. The report provides detailed coverage o ... Read More

• Anti-CD274 (PD-L1) Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,500

  Anti-CD274 (PD-L1) Antibody - Pipeline Insight, 2024 “Anti-CD274 (PD-L1) Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD274 (PD-L1) Antibody development. The report p ... Read More

• Anti-CD52 Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti-CD52 Antibody - Pipeline Insight, 2024 “Anti-CD52 Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD52 Antibody development. The report provides detailed coverage o ... Read More

• Anti-CD3 Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,500

  Anti-CD3 Antibody - Pipeline Insight, 2024 “Anti-CD3 Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD3 Antibody development. The report provides detailed coverage of t ... Read More

• Anti-CD33 Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti-CD33 Antibody - Pipeline Insight, 2024 “Anti-CD33 Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD33 Antibody development. The report provides detailed coverage o ... Read More

• Anti-CD28 Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti-CD28 Antibody - Pipeline Insight, 2024 “Anti-CD28 Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD28 Antibody development. The report provides detailed coverage o ... Read More

• Anti-CD38 antibody- Pipeline Insight, 2023

  Nov 01, 2023  |  Published by: DelveInsight  |  USD 1,500

  Anti-CD38 antibody- Pipeline Insight, 2023 DelveInsight’s, “Anti-CD38 antibody- Pipeline Insight, 2023” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Anti-CD38 antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical ... Read More

• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - Market Insight, Epidemiology And Market Forecast - 2032

  Jul 01, 2023  |  Published by: DelveInsight  |  USD 7,500

  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - Market Insight, Epidemiology And Market Forecast - 2032 Key Highlights Anti-neutrophilic cytoplasmic antibody (ANCA) associated vasculitis is a heterogeneous group of rare autoimmune conditions. ANCA Associated Vasculitis includes three ma ... Read More

• Monoclonal antibodies - Competitive landscape, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 5,000

  Monoclonal antibodies - Competitive landscape, 2023 DelveInsight’s, “Monoclonal antibodies - Competitive landscape, 2023,” report provides comprehensive insights about 180+ companies and 230+ drugs in Monoclonal antibodies Competitive landscape. It covers the therapeutics assessment by product type ... Read More

• Bispecific antibody - Competitive landscape, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 5,000

  Bispecific antibody - Competitive landscape, 2023 DelveInsight’s, “Bispecific antibody - Competitive landscape, 2023,” report provides comprehensive insights about 250+ companies and 300+ drugs in Bispecific antibody Competitive landscape. It covers the therapeutics assessment by product type, stage ... Read More

• Anti-neutrophilic cytoplasmic antibody (ANCA) associated Vasculitis - Epidemiology Forecast - 2032

  Apr 01, 2023  |  Published by: DelveInsight  |  USD 3,950

  Anti-neutrophilic cytoplasmic antibody (ANCA) associated Vasculitis - Epidemiology Forecast - 2032 Key Highlights Anti-neutrophilic cytoplasmic antibody (ANCA) associated vasculitis is a heterogeneous group of rare autoimmune conditions. ANCA Associated Vasculitis includes three main diseases, which ... Read More

• Antibody–drug Conjugates (ADCs) in Oncology- Competitive Landscape - 2023

  Apr 01, 2023  |  Published by: DelveInsight  |  USD 3,950

  Antibody–drug Conjugates (ADCs) in Oncology- Competitive Landscape - 2023 DelveInsight’s “Antibody–drug Conjugates (ADCs) Competitive landscape, 2023” report provides comprehensive insights about 30+ companies and 35+ drugs in ADCs. It covers the therapeutics assessment by product type, stage, route ... Read More

• Birtamimab Emerging Drug Insight and Market Forecast – 2032

  Dec 01, 2022  |  Published by: DelveInsight  |  USD 3,250

  Birtamimab Emerging Drug Insight and Market Forecast – 2032 “Birtamimab Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about Birtamimab for AL Amyloidosis in the 7MM. A detailed picture of the Birtamimab for AL Amyloidosis in the 7MM, i.e., United States, EU ... Read More

• Omburtamab Emerging Drug Insight and Market Forecast – 2032

  Sep 01, 2022  |  Published by: DelveInsight  |  USD 3,250

  Omburtamab Emerging Drug Insight and Market Forecast – 2032 “Omburtamab Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about Omburtamab for Leptomeningeal Metastases in the 7MM. A detailed picture of the Omburtamab for Leptomeningeal Metastases in the 7MM, i ... Read More

• Antibody-mediated Rejection - Market Insight, Epidemiology And Market Forecast - 2032

  Aug 01, 2022  |  Published by: DelveInsight  |  USD 7,500

  Antibody-mediated Rejection - Market Insight, Epidemiology And Market Forecast - 2032 DelveInsight's ""Antibody-Mediated Rejection (AMR) - Market Insights, Epidemiology, and Market Forecast-2032"" report delivers an in-depth understanding of the Antibody-Mediated Rejection, historical and forecasted ... Read More

• Intravenous Immunoglobulin (IVIG) - Epidemiology Forecast - 2032

  Jan 01, 2022  |  Published by: DelveInsight  |  USD 3,950

  DelveInsight's "" Intravenous Immunoglobulin (IVIG) - Epidemiology Forecast to 2032 "" report delivers an in-depth understanding of the disease, historical and forecasted Intravenous Immunoglobulin (IVIG) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the U ... Read More

• Antibody Drug Conjugate - Market Insight, Epidemiology and Market Forecast -2032

  Jan 01, 2022  |  Published by: DelveInsight  |  USD 7,500

  DelveInsight's "" Antibody Drug Conjugate- Market Insights, Epidemiology, and Market Forecast-2032 "" report delivers an in-depth understanding of the Antibody Drug Conjugate, historical and forecasted epidemiology as well as the Antibody Drug Conjugate market trends in the United States, EU5 (Germa ... Read More

• Anti-CD80 Antibody - Pipeline Insight, 2022

  Jan 01, 2022  |  Published by: DelveInsight  |  USD 1,250

  “ Anti-CD80 Antibody - Pipeline Insight, 2022 ” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD80 Antibody development. The report provides detailed coverage of the pipeline landscape for this mechanis ... Read More

• Anti-Dickkopf-1 (Dkk-1) Antibody - Pipeline Insight, 2022

  Jan 01, 2022  |  Published by: DelveInsight  |  USD 1,250

  “ Anti-Dickkopf-1 (Dkk-1) Antibody - Pipeline Insight, 2022 ” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-Dickkopf-1 (Dkk-1) Antibody development. The report provides detailed coverage of the pipeline ... Read More

• Anti-CD19 Antibody - Pipeline Insight, 2022

  Jan 01, 2022  |  Published by: DelveInsight  |  USD 1,250

  “ Anti-CD19 Antibody - Pipeline Insight, 2022 ” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD19 Antibody development. The report provides detailed coverage of the pipeline landscape for this mechanis ... Read More

• Anti-CD274 (PD-L1) Antibody - Pipeline Insight, 2022

  Jan 01, 2022  |  Published by: DelveInsight  |  USD 1,500

  “ Anti-CD274 (PD-L1) Antibody - Pipeline Insight, 2022 ” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD274 (PD-L1) Antibody development. The report provides detailed coverage of the pipeline landscape ... Read More

< prev 1 2 3 next >